ExploreOncoDNAKnowledgebase:avaluableoncologyresource

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

 Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Our Blog & 

Unlock a goldmine of cutting-edge knowledge and resources on our blog, where we delve into the forefront of precision medicine, offering expert perspectives, actionable insights, and game-changing discoveries to empower your journey in shaping the future of healthcare.  

 Gridbuilder ᵂᴾ Plugin (https://wpgridbuilder.com) 

Category
WebinarWhite paperArticleCase of the MonthLab CasePosterPress ReleaseScientific Application NoteScientific ReviewTestimonialVideo 

1 - 32 of 115 results 

 Case of the Month
March: 42-year-old male with a metastatic colorectal cancer2 min readingMar 18th

Here we will describe the case of a man of 42 years old diagnosed in 2021 with metastatic colorectal cancer. Read more → Press Release
Leading European oncology center Gustave Roussy adopts OncoDNA’s OncoDEEP® Kit and automates library preparation and Target Enrichment using Bravo instrument.Feb 28th

Leading French and European comprehensive cancer center selects the OncoDEEP® Kit as the most complete solution with the highest number of relevant oncology biomarkers for use in its molecular laboratory.   Gosselies, Belgium and Paris,...Read more → Article
OncoDNA’s Evry laboratory atteins CLIA certification and CAP accreditation to reinforce its global clinical trial testing servicesFeb 23rd

In the ever-evolving landscape of oncology clinical trials, the pursuit of precision has become synonymous with progress. In this era where tailored therapies hold the promise of improved patient outcomes, the foundation of reliable and...Read more → Case of the Month
February: 40-year-old male with a stage IV glioma cancer2 min readingFeb 20th

OncoDEEP® identifies rare mutations & personalizes treatment for a 40-year-old male with a stage IV glioma cancerRead more → Webinar
Advancing personalized cancer treatment: Webinar ReplayFeb 19th

Webinar replay available now: Unlocking precision medicine through expert NGS panel design Discover the Future of Personalized Cancer Treatment Thank you for your interest in our groundbreaking webinar on the latest advancements in cancer research...Read more → Poster
Genome-wide circulating tumor DNA for monitoring treatment response and metastatic relapse in bladder cancer5 min readingJan 22nd

Introduction: The integration of neoadjuvant chemotherapy (NAC) followed by radical cystectomy (CX) marks a pivotal advancement in treating localized muscle-invasive bladder cancer (MIBC). Despite these efforts, approximately 45% of MIBC patients experience metastatic recurrence within...Read more →

 Webinar
Advancing personalized cancer treatment: explore the synergy of Twist Bioscience and OncoDNA in our webinarJan 22nd

Unlocking precision medicine through expert NGS panel design Tuesday, February 13, 20244:00 PM CEST By Dr. Marcel Trautmann, Koenraad Eycken, Dr. James Flynn Join our webinar to discover revolutionary insights into personalised cancer treatment with...Read more →

 Press Release
Revolutionary treatment for colorectal cancer: OncoDNA joins the PDC*neo+ project for a personalised therapeutic vaccineJan 17th

Medical research is taking a quantum leap forward with the PDC*neo+ project, promising a significant progress in the treatment of colorectal cancer. Thanks to OncoDNA’s unique expertise in neoantigen identification and circulating tumour DNA (ctDNA)...Read more →

 Case of the Month
January: 45-year-old male with an intrahepatic cholangiocarcinoma2 min readingJan 16th

We will describe the case of a 45 year old man diagnosed with an intrahepatic cholangiocarcinoma in 2022. He was treated by surgery and had several cycle of chemotherapies. The patient shows signs of resistance...Read more → Poster
Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers5 min readingJan 8th

Overview: The technique of liquid biopsy represents a groundbreaking non-invasive method for tracking cancer progression and remission, particularly during treatment and follow-up phases. Despite its promise, the application of liquid biopsy in pediatric brain cancer...Read more →

 Press Release
OncoDNA laboratory has received the CAP accreditationJan 4th

Gosselies, January 4th – The Certificate of Accreditation has been issued to the IntegraGen laboratory by The College of American Pathologists (CAP) for having successfully met the Laboratory Accreditation Program Standards. “The CAP accreditation is a critical step for OncoDNA, and we...Read more → Case of the Month
December: 52-year-old male with a stage IV gastric cancer2 min readingDec 19th

Case description: Gastric cancer is one of the leading causes of cancer-related mortality worldwide, with a 5-year survival rate ranging from 5% to 20% for advanced-stage cases (PMID: 30853093). We describe the case of a...Read more → Poster
Ultra-sensitive detection of MRD through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer5 min readingDec 12th

Overview: The pivotal role of early detection of cancer recurrence and the precise monitoring of minimal residual disease (MRD) after surgery cannot be overstated, especially in the context of non-small cell lung cancer (NSCLC) where...Read more →

 Press Release
OncoDEEP Kits enable routine NGS workflow at the Institute of Pathology, Klinikum Region, Hanover, GermanyDec 4th

OncoDNA, a leading genomic and theranostic company specialising in precision medicine for cancer treatment, today has announced the implementation of OncoDEEP® Kit in clinical routine by the Institute of Pathology at the Klinikum Region Hannover...Read more →

 Press Release
OncoDNA supports the extension of AURORA study to identify molecular changes driving metastatic breast cancerNov 23rd

OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, today has announced its support to the extension of the AURORA program, which aims to...Read more →

 Video
Decoding Cancer: OncoDEEP Kit revolutionises genomic analysis for personalised treatment

Join us in this video as Marcel Trautmann, Head of Molecular Diagnostics within the first German Department of Pathology and member of the German Network for Personalized Medicine (DNPM),  shares his firsthand experience with OncoDEEP®...20 minutesNov 15th

 Case of the Month
November: 68 year-old man with a Stage IV Prostate cancer2 min readingNov 14th

Case description: Prostate cancer is the fifth leading cause of cancer death in the world. When the cancer is localized, it is usually indolent, with a 5-year survival rate of nearly 100%. However, when the...Read more →

 Press Release
OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, NetherlandsNov 7th

OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, Netherlands The ETZ (Elisabeth-TweeSteden Hospital) is a leading hospital offering multiple clinical specialties including oncology and trauma across...Read more →

 Poster
ctDNA’s promise in early detection of MRD and recurrence prediction for Head and Neck Squamous Cell Carcinoma5 min readingNov 2nd

Two recent studies, led by the Institute Curie in collaboration with OncoDNA, have assessed the potential of circulating tumor DNA (ctDNA) as a biomarker for early detection of Molecular Residual Disease (MRD) and predicting recurrence...Read more →

 Case of the Month
October: 65 year-old woman with a Metastatic Breast Cancer with hormone receptor (HR)-positive2 min readingOct 31st

Case description: A 65 year-old woman was diagnosed with a metastatic breast cancer, hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. Thanks to our OncoDEEP analysis, we notably detected a variant PIK3CA...Read more →

 Press Release
OncoDNA launches the OncoSELECT Kit increasing laboratories capacity to provide liquid comprehensive genomic profiling in-houseOct 20th

OncoDNA launches the OncoSELECT Kit increasing laboratories capacity to provide liquid comprehensive genomic profiling in-house. Gosselies, Belgium, October 20th, 2023 – OncoDNA, a leading genomic and theranostic company specialising in precision medicine for cancer treatment,...Read more →

 Poster
Analytic validation and implementation of OncoDEEP: A pan-cancer comprehensive genomic profiling NGS assay for assessing homologous recombination deficiency (HRD)Oct 19th

Comprehensive genomic profiling (CGP) and reliable molecular characterization of solid tumors using NGS technology has become a key tool to facilitate biomarker-matched therapy selection. With a broad spectrum of therapies already approved or in clinical...Read more →

 Press Release
C2i Genomics and OncoDNA Begin Molecular Residual Disease Testing Across EuropeOct 19th

OncoDNA’s lab in France is the first in the EU to enable access to the C2inform test for clinical decision-making Gosselies — (October 19, 2023) — OncoDNA, a genomic and theranostic company specializing in precision...Read more →

 Scientific Review
Scientific Review: Latest Discoveries in OncologyOct 3rd

In a rapidly evolving medical landscape, staying updated with the latest breakthroughs is crucial. Our team of experts constantly monitors the field to bring you the most relevant and groundbreaking news. This month, we’ve handpicked...Read more →

 Lab Case
Enhancing HRD Genomic Scar Result Interpretation: New Insights and Strategies5 min readingSep 29th

What is HRD Genomic Scar? The HRD Genomic Scar (GS) is essentially a collection of genetic changes or signatures that indicate a cell’s inability to repair DNA damage effectively using this specific DNA repair pathway....Read more →

 Case of the Month
September: 53 year-old man with Metastatic Colorectal Cancer2 min readingSep 29th

Case description: A 53 year-old man was diagnosed with metastatic colorectal cancer. In 2023, the primary sample was tested using our OncoDEEP® Kit. The analysis revealed a FMN1-NTRK3 gene fusion for this patient and a...Read more →

 Video
Testimonial of OncoDNA’s Journey through its founder’s words

Dive Deep into OncoDNA’s journey tells by its founder Jean-Pol Detiffe !   In this video interview, you’ll discover the inspiration behind OncoDNA’s tests and its pioneering decentralized solution: OncoDEEP Kit. But that’s not all!...5 minutesAug 22nd

 Case of the Month
July: 53 year-old man with Non-Small Cell Lung Cancer2 min readingJul 24th

Case description: A 53 year-old man was diagnosed with a metastatic Non-Small Cell Lung Cancer (mNSCLC) in 2021. This patient was a non-smoker. In 2022, a biopsy from a bone metastasis was tested using our...Read more →

 Scientific Application Note
Cancer Management: Breast Cancer5 min readingJul 24th

What is Breast Cancer? With an estimated 2.26 million new cancer cases and 685 000 deaths in women, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death in 2020,...Read more →

 Testimonial
Revolutionizing precision medicine: OncoDNA’s data innovation story5 min readingJul 3rd

Once upon a time, in a world where personalized medicine was a luxury reserved for the few, a small but passionate group embarked on an audacious journey to change precision medicine. It was a crazy...Read more →

 Press Release
OncoDNA announces the closing of a round C financing of 6,5 M€Jul 3rd

OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, today announced the closing of a Round C financing of 6,5 M€, entirely subscribed by...Read more → Lab Case
Revolutionizing laboratory operations with OncoDEEP® Kit4 min readingJun 18th

Biomarker testing is critical to learning more about each patient’s tumor type and can be used to help determine treatment options. Based on the test results, patients may be matched with targeted therapies aimed at...Read more → 

Stay in the know 

	Get the latest resources, news and more.	

monthly
PhoneThis field is for validation purposes and should be left unchanged.

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Resources

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712101530